Interferon aerosol propellant

A technology of aerosol inhalation and interferon, which can be used in aerosol delivery, antiviral agents, respiratory diseases, etc., and can solve the problems of late discovery and reporting of type III interferon.

CN105920586AInactive Publication Date: 2016-09-07BEIJING TRI PRIME GENE PHARMA CO LTD
10 Cites 6 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2016-09-07
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the field of a biotechnology medicine preparation, and relates to an interferon aerosol propellant. The single-time administration dosage of the interferon aerosol contains 1 to 100 [mu]g of interferon and a proper number of aerosol propellant pharmaceutically acceptable auxiliary materials; and the interferon consists of interferon Alpha and interferon Lambda with the weight ratio being (1:19) to (19:1). Compared with the aerosol propellant singly using the interferon Alpha and the aerosol propellant singly using the interferon Lambda, the interferon aerosol propellant provided by the invention obviously improves the curative effect when being used for treating viral pneumonia.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention generally relates to the respiratory tract and pulmonary administration preparations of interferon, and particularly relates to the nebulized inhalation preparation of interferon. Background technique

[0002] Viral pneumonia is a common disease in infants and young children, which seriously endangers the life and health of infants and young children. According to incomplete statistics, more than 90% of infants and young children have been infected with viral pneumonia before the age of 2, of which more than 80% of the cases are within 1 year old, the peak age of onset is 2-6 months, and severe cases can be seen in 1-6 months . The death rate of infants and young children caused by infection of viral pneumonia is 0.5%-2.0% in developed countries, up to 7% in developing countries, and it is the leading cause of infant death in my country. In addition, viral pneumonia is very contagious and reinfectious. It has been reported that ...

Examples

Embodiment 1

[0042] Embodiment 1: the preparation of interferon atomized inhalation

[0043] The aerosol inhalation of different formulations of interferon was prepared according to the formula composition in the following table 1, wherein "PB" is disodium hydrogen phosphate-sodium dihydrogen phosphate buffer solution (pH7.0).

[0044] The formula composition of table 1 interferon atomized inhalation

[0045]

[0046]

[0047]

Embodiment 2

[0048] Embodiment 2: the animal test of interferon atomized inhalation treatment viral pneumonia

[0049] 1) RSV virus culture

[0050] The RSV standard strain RSV-Long (quoted from the Beijing Institute of Pediatrics) was inoculated on Hep-2 cells, harvested when the cytopathic rate reached more than 80%, and the virus liquid was frozen in liquid nitrogen and stored at 37°C Melt, centrifuge at 1000rpm for 10 minutes, and take the supernatant for later use.

[0051] 2) Establishment of RSV mouse infection model

[0052] Take 172 6-7 week-old Balb / c mice, half male and half male, all anesthetized with ether, and respectively instill 10 6 PFU / ml RSV virus liquid 0.1ml, instill the virus once a day, a total of 2 infusions, on the 3rd day, the mice showed positive reactions such as piloerection, restlessness, shortness of breath, and abdominal muscle convulsions, indicating that the RSV infection mouse model was successfully established.

[0053] 3) Grouping and administration ...